logo
Here's what Wall Street thinks about Tesla's second-quarter results

Here's what Wall Street thinks about Tesla's second-quarter results

CNBC6 days ago
Wall Street ratings were a mixed bag after Tesla's second-quarter financial results. Tesla on Wednesday reported a second straight quarter of declining automotive sales , which came in at $16.7 billion for the period, down from $19.9 billion in the same quarter last year. The company also missed on top and bottom lines. Shares of the electric vehicle maker plunged 6% in premarket trading, piling on its roughly 17.7% year to date loss. Tesla has struggled in key markets such as China and Europe and notably lost market share to Chinese companies that have released lower cost EV models. Still, analysts have a wide range of ratings and price targets on Tesla shares. It's a company that bulls tend to stick by for its future value in technologies such as robotaxis, not necessarily its near-term innovation. Analysts polled by LSEG have a consensus price target on Tesla that implies more than 9% downside for Tesla shares. Of the 54 analysts covering the stock, five rate it a strong buy, while 19 rate it a buy and 20 maintain a hold. Ten have an underperform or sell rating on shares. Here's a look at what some Wall Street majors said after the EV maker's earnings release: Goldman Sachs keeps neutral rating, lifts price target to $300 Analyst Mark Delaney raised his 12-month price target to $300 from $285. He said he expects Tesla's revenue growth and profits to improve in 2026, but is keeping his 2025-2027 estimates below the FactSet consensus. "We believe a key focus for investors going forward will be the ability for revenue and profits to reaccelerate driven by Tesla's AI enabled products (e.g. robotaxis, FSD) and new vehicle launches against a more difficult policy environment and given competition," Delaney said in a Wednesday note. "Management did note the potential for the end of IRA EV purchase incentives in 4Q to temporarily pressure fundamentals, but the shift to AI enabled products including robotaxis/FSD and Optimus would be a substantial long-term driver." Wells Fargo reiterates underweight rating, $120 price target Wells Fargo sees major room for downside ahead. Analyst Colin Langan's price target implies Tesla shares stand to lose nearly 64% from their latest close of $332.56 per share. Tesla shares are down in post-earnings trading "despite a Q2 op margin beat as fundamentals look worse into 2H. TSLA did not provide new delivery guidance & warned of added pressure from tariffs, IRA & OBBB. We agree with 2H concerns & remain UW," Langan wrote in a Thursday note. He remains cautious on robotaxis, even after CEO Elon Musk's bullish commentary that robotaxis will "probably address half the population of the U.S." by year-end, and that Tesla expects an Optimus 3 prototype by the end of the year to scale next year. Langan said that scaling robotaxis and Optimus humanoids could take longer than expected, which he believes raises risks as Tesla's core business weakens. Morgan Stanley maintains overweight rating, $410 price target Analyst Adam Jonas is a well-known Tesla bull. He reiterated Tesla as a top pick and kept a target price that implies about 23% potential upside. Still, Jonas lowered his fiscal year 2025 earnings per share expectations by 14% compared to prior forecasts, mostly driven by lower deliveries and higher operating expenses. "2Q numbers were a slight beat with FCF near break-even. Tesla is crossing the chasm to autonomy while absorbing slower volume, EV incentive elimination, tariffs and investing in new initiatives that may not make margins for years," Jonas said in a note about Tesla's results. "Our OW rating and $410 price target are underpinned by our belief that Tesla's capabilities in key areas of physical AI ... offer growth and margin opportunities that greatly exceed those of the traditional EV business, which is under pressure," he added. "we struggle to think of any other company as well positioned as Tesla in terms of data, robotics, energy, AI, manufacturing and supporting infrastructure Bank of America reiterates neutral rating, $341 price target Analyst Federico Merendi anticipates "rough quarters ahead" for Tesla, echoing Musk's commentary. His neutral rating on the stock relies on Tesla's current market advantage in autonomous driving initiatives and physical AI applications, he said. "Tesla commentary on future developments in terms of real-world AI (Autonomous vehicles/robotaxi and Optimus) remains bullish. However, the company is facing challenging times," he wrote in a note to clients. "Commentary also suggests that the tariff impact may increase in the future. However, by end of 2026, management thinks that Tesla's economics will be compelling with autonomy at scale." Evercore ISI maintains in-line rating, $235 price target Analyst Chris McNally expects Tesla's third-quarter results to see the downbeat effects of slower EV launches and tariff impacts. "The LT negative EPS revision trend has continued, unabated," he said in a note. "We believe there will be a sharper cons move post Q3."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rosen Law Firm Encourages Tungray Technologies Inc Investors to Inquire About Securities Class Action Investigation
Rosen Law Firm Encourages Tungray Technologies Inc Investors to Inquire About Securities Class Action Investigation

Associated Press

timea few seconds ago

  • Associated Press

Rosen Law Firm Encourages Tungray Technologies Inc Investors to Inquire About Securities Class Action Investigation

NEW YORK, July 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tungray Technologies Inc (NASDAQ: TRSG) resulting from allegations that Tungray Technologies may have issued materially misleading business information to the investing public. So What: If you purchased Tungray Technologies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. What is this about: On December 31, 2024, Tungray Technologies filed a current report with the U.S. Securities and Exchange Commission on Form 6-K. The current report stated that on 'December 30, 2024, the Board of Directors of Tungray Technologies Inc (the 'Company'), upon recommendation of the Audit Committee and following discussions with management, determined that the Company's financial statements for the years ended December 31, 2023, 2022 and 2021 included in the Company's Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission on April 26, 2024 (the '20-F'), should no longer be relied upon. Similarly, related reports, press releases, earnings releases, and investor communications describing the Company's financial statements for these periods should no longer be relied upon.' Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] View original content to download multimedia: SOURCE THE ROSEN LAW FIRM, P. A.

FTRE DEADLINE: ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Fortrea Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 1 Deadline in Securities Class Action
FTRE DEADLINE: ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Fortrea Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 1 Deadline in Securities Class Action

Associated Press

timea few seconds ago

  • Associated Press

FTRE DEADLINE: ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Fortrea Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 1 Deadline in Securities Class Action

New York, New York--(Newsfile Corp. - July 30, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the 'Class Period'), of the important August 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Fortrea securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Fortrea class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to Fortrea's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the transition service agreements ('TSAs'); (3) as a result, Fortrea's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of Fortrea's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Fortrea's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Fortrea class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Associated Press

timea few seconds ago

  • Associated Press

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

New York, New York--(Newsfile Corp. - July 30, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the 'Class Period'), of the important August 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sarepta securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Sarepta class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (3) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (4) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Sarepta class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store